#USA #Veeva Systems #Pleasanton, California #Zifo #qcKen

Strengthening Quality Control in Biopharma

In an exciting development for the biopharmaceutical sector, Veeva Systems, a leading cloud software provider, announced a strategic partnership with Zifo, a global leader in data integration and management. This collaboration aims to modernize quality control (QC) operations, addressing challenges that many biopharma companies face in today's fast-paced environment.

The Partnership's Objectives

The primary goal of this new alliance is to integrate Veeva's Laboratory Information Management System (LIMS) with Zifo's data management platform, known as qcKen. Through this integration, biopharma companies will be able to effortlessly import data from various source documents and existing LIMS into Veeva LIMS, subsequently reducing the complexity and costs associated with configuring master lab data.

According to Kannan Jagamoorthy, the general manager and head of Zifo North America, this partnership will facilitate a more efficient transition away from outdated QC systems. "We are excited to partner with Veeva to offer powerful solutions to the life sciences industry. Our collaboration will help customers expedite their adoption of Veeva LIMS to streamline operations," Jagamoorthy stated.

Holistic Quality Assurance

Veeva Systems is already recognized for its holistic approach to ensuring both quality assurance (QA) and quality control (QC) within the life sciences sector. By leveraging Zifo's advanced qcKen platform, organizations can accelerate the creation of test and specification data, making implementations and site deployments more streamlined.

Ashley McMillan, the senior director of Veeva LIMS strategy, highlighted that Veeva LIMS was specifically designed for life sciences entities aiming to enhance their QC operations. "Partnering with Zifo allows customers to implement Veeva LIMS and realize value much quicker, accelerating QC modernization initiatives," said McMillan, indicating the fast-tracked benefits this partnership brings.

Advantages of the Integration

The integration promises several notable advantages:

• - Reduced Complexity: Simplifying master data configuration during LIMS implementation.
• - Cost Efficiency: Lowering operational costs associated with legacy systems.
• - Faster Implementation: Expedites the adoption and usage of Veeva LIMS across various biopharma companies.
• - Enhanced Accuracy: Promoting greater accuracy in quality business processes, essential for Good Manufacturing Practices (GMP).
• - Accelerated ROI: Delivering a faster return on investment for companies that adopt the new tools, allowing them to channel resources into innovation and development.

The announcement of this partnership reveals a vital step forward for biopharmaceutical companies looking to enhance their QC processes. As companies grapple with the complexities of modernizing their operational frameworks, the combined strengths of Veeva and Zifo could prove transformative.

About Veeva Systems

Founded as a Public Benefit Corporation, Veeva Systems emphasizes innovation and customer success in the life sciences domain. Serving over 1,000 clients ranging from major biopharmaceutical firms to smaller startups, Veeva is committed to balancing the interests of its stakeholders. More information can be found at veeva.com.

About Zifo

Zifo is a leader in enabling AI and data-driven solutions for science-driven organizations. The company boasts extensive expertise across various sectors including pharma, biotech, and manufacturing. Trusted globally by over 190 organizations for its innovative solutions, Zifo stands as the partner of choice for advancing scientific innovation. To learn more, visit zifornd.com.

Conclusion

As the biopharma industry continues to evolve, partnerships like the one between Veeva and Zifo represent a significant opportunity for companies to modernize their quality control processes. By utilizing cutting-edge technology to streamline operations and ensure compliance, biopharmaceutical organizations can focus on what they do best: delivering high-quality products to patients worldwide.